Expert Opinion on Emerging Drugs
Expert Opinion on Emerging Drugs is a quarterly peer-reviewed journal published by Taylor & Francis, covering emerging drugs in clinical development. Founded in 1996, it provides expert evaluations of the most important emerging drugs in Phase II and III clinical trials, with a 2025 impact factor of 3.8, indexed in SCIE.《新兴药物专家意见》（Expert Opinion on Emerging Drugs, 简称 EOED）是由 Taylor & Francis 出版的季刊同行评审期刊，涵盖临床开发中的新兴药物。该刊创刊于 1996 年，提供 II 期与 III 期临床试验中最重要新兴药物的专家评价，2025 年影响因子为 3.8，被 SCIE 收录。
Scope
The journal's stated aim is to provide an expert evaluation of the most important emerging drugs in Phase II and III clinical trials across all therapy areas, with its official scope covering:刊物官方宗旨为提供所有治疗领域 II 期与 III 期临床试验中最重要新兴药物的专家评价，官方声明的征稿范围包括：
- Emerging drugs evaluation: expert evaluations of drugs in Phase II and III clinical development, assessing their potential impact on the current management of specific diseases.新兴药物评价： 对 II 期与 III 期临床开发中药物的专家评价，评估其对特定疾病当前管理的潜在影响。
- Drug discovery and development: studies on the drug discovery and development pipeline, including new molecular entities and novel therapeutic approaches.药物发现与开发： 关于药物发现与开发管线的研究，包括新分子实体与新型治疗方法。
- Clinical trials: expert reviews on the design, conduct, and outcomes of clinical trials for emerging drugs across all therapeutic areas.临床试验： 关于所有治疗领域新兴药物临床试验设计、实施与结局的专家综述。
- Therapeutic areas: evaluations of emerging drugs across therapeutic areas including oncology, infectious disease, central nervous system, cardiovascular, and inflammation.治疗领域： 对肿瘤、传染病、中枢神经系统、心血管与炎症等治疗领域新兴药物的评价。
- Article types: the journal publishes expert reviews, drug evaluations, and editorial perspectives on emerging drugs and their clinical potential.栏目设置： 该刊发表关于新兴药物及其临床潜力的专家综述、药物评价与编辑观点。
History
- Founding: the journal was established in 1996 as part of the Expert Opinion series, originally titled Emerging Drugs.创刊： 该刊于 1996 年作为专家意见系列之一创刊，原名为《新兴药物》。
- Taylor & Francis publication: EOED is published by Taylor & Francis under the Expert Opinion series, ensuring high editorial standards and expert contributions.Taylor & Francis 出版： EOED 由 Taylor & Francis 出版，隶属专家意见系列，确保高编辑标准与专家贡献。
- Clinical development focus: throughout its history, the journal has specialized in evaluating drugs in the critical Phase II and III stages of clinical development.临床开发聚焦： 在其发展历程中，该刊专注于评价临床开发关键 II 期与 III 期阶段的药物。
- Publication frequency: the journal publishes quarterly, providing regular updates on emerging drugs across all therapeutic areas.出版频率： 该刊每季出版，定期更新所有治疗领域的新兴药物进展。
Editors
The journal is led by an editor-in-chief supported by section editors and an editorial board:该刊由主编领导，栏目编辑与编委会协助工作：
- Editor-in-chief: Howard Trachtman of the University of Michigan, Ann Arbor, Michigan, United States, serves as the editor-in-chief.主编： 美国密歇根州安娜堡密歇根大学的霍华德·特拉赫特曼（Howard Trachtman）担任主编。
- Section editors: the editor-in-chief is supported by section editors with expertise across major therapeutic areas.栏目编辑： 主编由具有主要治疗领域专长的栏目编辑协助。
- Editorial board: the journal has a large international editorial board comprising clinical pharmacologists and drug development experts from leading institutions and companies worldwide.编委会： 该刊拥有大型国际编委会，成员为来自全球顶尖机构与企业的临床药理学家与药物开发专家。
- Open access option: authors can choose to publish open access in this journal, making their articles freely available to readers upon publication in exchange for an article processing charge.开放获取选项： 作者可选择在该刊发表开放获取文章，使论文发表后即向读者免费开放，并支付文章处理费。